Oyster Raises 60 Million Dollars for Tau Degraders

Company Oyster Therapeutics (formerly Kesmalea Therapeutics) Event Type Series A financing ($60 million) Modality Small bifunctional protein degrader (SELFTAC) Asset Undisclosed lead tau degrader Target Tau Disease Area Alzheimer’s disease and other tauopathies Summary Oyster Therapeutics, formerly Kesmalea, announced a $60 million Series A led…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *